- Home
- REPL vs MCBS Comparison
REPL vs MCBS Comparison
Compare REPL & MCBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- MCBS
- Stock Information
- Founded
- REPL 2015
- MCBS 2006
- Country
- REPL United States
- MCBS United States
- Employees
- REPL N/A
- MCBS N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- MCBS Major Banks
- Sector
- REPL Health Care
- MCBS Finance
- Exchange
- REPL Nasdaq
- MCBS Nasdaq
- Market Cap
- REPL 757.8M
- MCBS 745.5M
- IPO Year
- REPL 2018
- MCBS 2019
- Fundamental
- Price
- REPL $9.21
- MCBS $29.30
- Analyst Decision
- REPL Strong Buy
- MCBS Hold
- Analyst Count
- REPL 7
- MCBS 1
- Target Price
- REPL $20.83
- MCBS $34.00
- AVG Volume (30 Days)
- REPL 1.1M
- MCBS 48.5K
- Earning Date
- REPL 08-07-2025
- MCBS 07-18-2025
- Dividend Yield
- REPL N/A
- MCBS 3.22%
- EPS Growth
- REPL N/A
- MCBS 30.91
- EPS
- REPL N/A
- MCBS 2.58
- Revenue
- REPL N/A
- MCBS $143,775,000.00
- Revenue This Year
- REPL N/A
- MCBS $16.00
- Revenue Next Year
- REPL N/A
- MCBS $31.75
- P/E Ratio
- REPL N/A
- MCBS $11.08
- Revenue Growth
- REPL N/A
- MCBS 19.70
- 52 Week Low
- REPL $6.44
- MCBS $24.24
- 52 Week High
- REPL $17.00
- MCBS $36.15
- Technical
- Relative Strength Index (RSI)
- REPL 53.47
- MCBS 55.48
- Support Level
- REPL $9.15
- MCBS $27.73
- Resistance Level
- REPL $9.64
- MCBS $28.71
- Average True Range (ATR)
- REPL 0.50
- MCBS 0.47
- MACD
- REPL -0.06
- MCBS 0.13
- Stochastic Oscillator
- REPL 50.57
- MCBS 77.00
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.